XNCR — Xencor, Inc. stock price, charts and financials

Latest market price

21.36

+0.55+2.64%

Overview Short InterestFilings

XNCRQT78Xencor, Inc.·NASDAQ

Overview Short InterestFilings

21.36+2.64%

Loading chart...

Signal & projected range

Earnings big beat — drift (PEAD)Historical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

AUPH-2.45%$15.46 MESO+4.71%$16.69 ZBIO-0.83%$32.16 GHRS-1.62%$29.78 TSHA-1.51%$6.46 STOK-1.22%$32.31 ABCL+39.97%$9.70 VRDN-3.29%$22.81

Snapshot

Index	-	P/E	-	EPS (ttm)	-2.29	Insider Own	17.35%	Shs Outstand	74.14M	Perf Week	2.97%

Market Cap	1.54B	Forward P/E	-	EPS next Y	-3.27	Insider Trans	-0.63%	Shs Float	54.42M	Perf Month	29.17%

Enterprise Value	1.56B	PEG	0.13	EPS next Q	-	Inst Own	-	Short Float	19.92%	Perf Quarter	69.05%

Income	-159.69M	P/S	14.70	EPS this Y	-32.13%	Inst Trans	-	Short Ratio	13.22	Perf Half Y	92.33%

Sales	104.97M	P/B	3.14	EPS next Y	-8.12%	ROA	-22.53%	Short Interest	10.84M	Perf YTD	35.92%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-28.66%	52W High	22.54 -5.24%	Perf Year	177.84%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-33.40%	52W Low	7.10 200.72%	Perf 3Y	-11.52%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-8.60% 0.48%	Gross Margin	43.31%	Volatility	6.65% 7.58%	Perf 5Y	-32.39%

Dividend TTM	-	EV/Sales	14.89	EPS Y/Y TTM	36.03%	Oper. Margin	-205.84%	ATR (14)	1.33	Perf 10Y	12.12%

Dividend Ex-Date	-	Quick Ratio	6.39	Sales Y/Y TTM	-10.91%	Profit Margin	-155.59%	RSI (14)	66.09	Recom	2.11

Dividend Gr. 3/5Y	-	Current Ratio	6.39	EPS Q/Q	-159.09%	SMA20	10.67%	Beta	0.83	Target Price	30.33

Payout	0.00%	Debt/Eq	0.13	Sales Q/Q	-84.85%	SMA50	33.24%	Rel Volume	1.18	Prev Close	20.81

Employees	260	LT Debt/Eq	0.22	Earnings	Nov 04	SMA200	49.17%	Avg Volume	926.79K	Price	21.36

IPO Date	Dec 03, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	-106.38% -83.79%	Net Debt/EBITDA	-0.17	Volume	1,092,614	Change	2.64%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Aug-06-26	Reiterated	RBC Capital	Outperform	$19 → $20
Aug-06-26	Reiterated	Cantor Fitzgerald	Overweight	$42 → $44
Jul-07-26	Reiterated	Truist Securities	Buy	$29 → $27
Mar-24-26	Downgrade	JP Morgan	Overweight → Neutral
Dec-17-25	Reiterated	Barclays	Overweight	$23 → $26
Nov-24-25	Initiated	Truist	Buy	$29
Nov-06-25	Reiterated	Cantor Fitzgerald	Overweight	$42
Oct-29-25	Upgrade	Barclays	Underweight → Overweight	$6.00 → $23
Oct-27-25	Reiterated	RBC Capital	Outperform	$31 → $18
Sep-16-25	Reiterated	Barclays	Underweight	$6.00

Latest News

Aug-06-26

Aug-06-2602:00PM

RBC Capital Maintains Outperform on Xencor, Raises Price Target to $20Benzinga

Aug-05-26

Aug-05-2606:26PM

Xencor (XNCR) Reports Q2 Loss, Beats Revenue Estimateszacks.com

04:01PM

Xencor Reports Second Quarter 2026 Financial Resultsbusinesswire.com

Jul-30-26

Jul-30-2609:39AM

Wedbush Reiterates Outperform on Xencor, Maintains $26 Price TargetBenzinga

Jul-29-26

Jul-29-2604:01PM

Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matterbusinesswire.com

Jul-20-26

Jul-20-2610:08AM

AMC Entertainment, IREN, Hut 8 And Other Big Stocks Moving Higher On MondayBenzinga

08:31AM

Xencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock?zacks.com

Jul-17-26

Jul-17-2609:11AM

Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinomabusinesswire.com

Jul-14-26

Jul-14-2604:01PM

Xencor: Bullish On Their Increasingly In-House Pipelineseekingalpha.com

Jul-07-26

Jul-07-2608:29AM

Truist Securities Maintains Buy on Xencor, Lowers Price Target to $27Benzinga

Company

Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in use, such as Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris, prescribed for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi, indicated for individuals with relapsed or refractory diffuse large B-cell lymphoma. Xencor maintains a robust and diverse pipeline of drug candidates advancing through various clinical trial stages. In oncology, this includes Plamotamab, a tumor-targeted antibody, currently undergoing Phase I trials for non-Hodgkin lymphoma; Vudalimab, a bispecific antibody in Phase II for metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab, also in Phase II for neuroendocrine tumors. Further cancer-focused programs comprise XmAb306, XmAb104, and XmAb841, all in Phase I for selected solid tumors; AMG 509, in Phase I for prostate cancer; XmAb819, being developed for renal cell carcinoma; and a program involving Novartis XmAb. In the infectious disease arena, Xencor is progressing VIR-3434 through Phase II for hepatitis B virus infection; VIR-2482 in Phase 1/2 for influenza A; VIR-7832 in a Phase 1b/2a trial for mild-to-moderate COVID-19; and is involved in the Phase 2/3 NIH ACTIV-2 trial for COVID-19 with BMS-986414 + BMS-986413. Beyond these, the company is developing XmAb564, a Phase I candidate for autoimmune diseases; Obexelimab, also for autoimmune conditions; AIMab7195, designed to reduce IgE levels for allergic responses; and Xpro1595, an experimental treatment for Alzheimer's disease, mild cognitive impairment, and depression. Xencor also holds a licensing agreement with Caris Life Sciences.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	105	126	110	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	60	11	228	—	—	—	—	—	—
Gross Profit	46	115	-117	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	65	64	59	—	—	—	—	—	—
Research and Development	256	239	228	—	—	—	—	—	—
Other Operating Expense	-60	-10	-226	—	—	—	—	—	—
Operating Income	-217	-178	-178	—	—	—	—	—	—
Interest Expense	27	32	37	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	83	120	-20	—	—	—	—	—	—
Net Income Before Taxes	-161	-89	-235	—	—	—	—	—	—
Income Taxes	2	3	2	—	—	—	—	—	—
Consolidated Net Income	-164	-92	-233	—	—	—	—	—	—
Net Income From Continuing Operations	-164	-92	-237	—	—	—	—	—	—
Net Income	-164	-92	-233	—	—	—	—	—	—
EPS (Recurring)	-2.17	-1.24	-3.58	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-2.17	-1.24	-3.58	—	—	—	—	—	—
EPS (Diluted)	-2.17	-1.24	-3.58	—	—	—	—	—	—
EBITDA	-123	-47	-186	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	15.46	8.99	13.58	—	—	—	—	—	—
Gross Margin	43.81	91.27	-106.36	—	—	—	—	—	—
Operating Margin	-206.67	-141.27	-161.82	—	—	—	—	—	—
Net Margin	-156.19	-73.02	-211.82	—	—	—	—	—	—
Shares Outstanding	76	74	65	—	—	—	—	—	—
Market Capitalization	1,623	1,133	1,494	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Feigal Ellen	Director	Jun 18 '26	Sale	13.06	6,843	89,370	12,340	Jun 22
GORMAN KEVIN CHARLES	Director	Jun 15 '26	Sale	12.31	7,527	92,657	11,378	Jun 17
GUSTAFSON KURT A	Director	Jun 15 '26	Sale	12.31	5,474	67,385	14,709	Jun 17
RANIERI RICHARD J	Director	Jun 15 '26	Sale	12.31	5,474	67,385	13,709	Jun 17
Montgomery Alan Bruce	Director	Jun 15 '26	Sale	12.31	5,064	62,338	15,547	Jun 17
Cornelissen Bart Jan	SR. VICE PRESIDENT & CFO	Apr 10 '26	Sale	12.29	3,499	42,990	75,898	Apr 13
Desjarlais John R	SR. VICE PRESIDENT & CSO	Mar 06 '26	Sale	11.02	2,502	27,571	263,831	Mar 09
Eckert Celia	SVP, GENERAL COUNSEL	Mar 06 '26	Sale	11.02	1,767	19,472	76,918	Mar 09
Dahiyat Bassil I	PRESIDENT & CEO	Mar 06 '26	Sale	11.02	6,606	72,796	546,316	Mar 09
Eckert Celia	SVP, GENERAL COUNSEL	Mar 05 '26	Sale	11.25	3,244	36,480	78,685	Mar 09
Desjarlais John R	SR. VICE PRESIDENT & CSO	Mar 05 '26	Sale	11.25	4,118	46,309	266,333	Mar 09
Cornelissen Bart Jan	SR. VICE PRESIDENT & CFO	Mar 05 '26	Sale	11.25	2,517	28,305	79,397	Mar 09
Dahiyat Bassil I	PRESIDENT & CEO	Mar 05 '26	Sale	11.25	14,870	167,221	552,922	Mar 09
Desjarlais John R	SR. VICE PRESIDENT & CSO	Mar 03 '26	Sale	11.90	2,663	31,677	270,451	Mar 04
Eckert Celia	SVP, GENERAL COUNSEL	Mar 03 '26	Sale	11.90	1,492	17,747	81,929	Mar 04

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.